Cargando…
RF26 | PSAT150 Growth Outcomes From the Phase 2 and Phase 3 Studies of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency: Comparisons With Published Literature and an International Growth Study Database
BACKGROUND: Somatrogon is a long-acting recombinant human growth hormone (hGH) currently in development as a once-weekly injectable treatment for children with growth hormone deficiency (GHD). In a phase 2 (NCT01592500) and a phase 3 (NCT02968004) study, patients received either once-weekly somatrog...
Autores principales: | Cara, Jose, Carlsson, Martin, Rosenfeld, Ron G, Wajnrajch, Michael P, Wang, Ronnie, Zadik, Zvi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625182/ http://dx.doi.org/10.1210/jendso/bvac150.1338 |
Ejemplares similares
-
OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment
por: Zadik, Zvi, et al.
Publicado: (2023) -
Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
por: Horikawa, Reiko, et al.
Publicado: (2022) -
OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial
por: Deal, Cheri L, et al.
Publicado: (2020) -
Somatrogon for growth hormone deficiency
Publicado: (2022) -
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
por: Deal, Cheri L, et al.
Publicado: (2022)